Table 1 Association of CDK5 expression and Ki-67 LI with clinicopathological features
From: Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study
Parameters | Total (n) | Expression of CDK5 n (%) | Z | P | Ki-67 relevant expression (2−ΔCq) | t | P | |
|---|---|---|---|---|---|---|---|---|
Negative | Positive | Mean ± SD | ||||||
Tissue | ||||||||
Normal tissue | 16 | 14 (87.5 %) | 2 (12.5 %) | −3.400 | 0.001 | 0.6062 ± 0.9518 | −12.464 | <0.001 |
Glioma | 152 | 65 (42.8 %) | 87 (57.2 %) | 11.4053 ± 10.2714 | ||||
Gender | ||||||||
Female | 49 | 23 (46.9 %) | 23 (53.1 %) | −0.014 | 0.989 | 10.6449 ± 10.4964 | 0.216 | 0.829 |
Male | 119 | 56 (47.1 %) | 63 (52.9 %) | 10.2664 ± 10.2259 | ||||
Age (median) | ||||||||
≤41.5 | 84 | 34 (40.5 %) | 40 (59.5 %) | −1.695 | 0.09 | 11.5940 ± 10.6489 | 1.542 | 0.125 |
>41.5 | 84 | 45 (53.6 %) | 39 (46.4 %) | 9.1595 ± 9.8001 | ||||
Grading1 | ||||||||
I–II | 67 | 39 (58.2 %) | 28 (41.8 %) | −3.406 | 0.001 | 2.0373 ± 1.8660 | −18.988 | <0.001 |
III–IV | 85 | 26 (30.6 %) | 59 (69.4 %) | 18.7864 ± 7.85763 | ||||
Grading2 | ||||||||
I | 23 | 15 (65.2 %) | 8 (34.8 %) | 15.482a | 0.001 | 2.0000 ± 2.5045 | 104.022b | <0.001 |
II | 44 | 24 (54.5 %) | 20 (45.5 %) | 2.0568 ± 1.4609 | ||||
III | 56 | 21 (37.5 %) | 35 (62.5 %) | 17.4571 ± 7.3644 | ||||
IV | 29 | 5 (17.2 %) | 24 (82.8 %) | 21.3621 ± 8.2639 | ||||
CDK5 | ||||||||
Low | 79 | 6.5380 ± 8.4147 | −4.928 | <0.001 | ||||
High | 89 | 13.7843 ± 10.6130 | ||||||
Ki-67 (median) | ||||||||
Low | 84 | 54 (64.3 %) | 30 (35.7 %) | −4.469 | <0.0001 | |||
High | 84 | 25 (29.8 %) | 59 (70.2 %) | |||||